FindTrial
Sign In

Novel coronavirus pneumonia (COVID-19) treated with different antiviral regimens: a medical records based study for analysis of therapeutic effect and length of stay of hospitalization

Novel coronavirus pneumonia treated with different antiviral regimens: analysis of therapeutic effect and length of stay

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040571
Enrollment
Unknown
Registered
2020-12-02
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

five groups:1. Lianhua Qingwen + oseltamivir group
2. Lianhua Qingwen + oseltamivir group + abidol group
3. Lianhua Qingwen + oseltamivir group + interferon group
4. Lianhua Qingwen + oseltamivir group + hormone group
5. Lianhua Qingwen + oseltamivir group + ribavirin group

Sponsors

Chongqing Shapingba District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 100 Years

Inclusion criteria

Inclusion criteria: From January to may 2020, about 200 mild patients diagnosed as covid-19 in the isolation ward of the first people's Hospital of Xiaogan City in Hubei Province were selected as the research objects

Exclusion criteria

Exclusion criteria: Non mild patients diagnosed with covid-19

Design outcomes

Primary

MeasureTime frame
effects, length of hospital stay;—

Countries

China

Contacts

Public ContactHuang Zi Yang

Chongqing Shapingba District People's Hospital

215136405@qq.com+86 13677644212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026